Summary of Significant Accounting Policies (Tables)

12 Months Ended

Feb. 29, 2020

Schedule of revenues

	Year Ended
	February 29,		March 2,		March 3,
	2020		2019		2018
	(52 Weeks)		(52 Weeks)		(52 Weeks)
Retail Pharmacy segment:
Pharmacy sales	$	10,354,293	$	10,391,539	$	10,328,376
Front-end sales		5,114,976		5,215,152		5,348,613
Other revenue		146,917		150,461		155,636
Total Retail Pharmacy segment		15,616,186		15,757,152		15,832,625
Pharmacy Services segment revenue		6,559,560		6,093,688		5,896,669
Intersegment elimination		(247,353)		(211,283)		(200,326)
Total revenue	$	21,928,393	$	21,639,557	$	21,528,968

Schedule of principal classes of products

	Percentage
Product Class	of Sales
Prescription drugs	67.0	%
Over-the-counter medications and personal care	11.0	%
Health and beauty aids	5.0	%
General merchandise and other	17.0	%

Schedule of disaggregation of revenue

In thousands	February 29, 2020
Retail Pharmacy segment:
Pharmacy sales	$	10,354,293
Front-end sales		5,114,976
Other revenue		146,917
Total Retail Pharmacy segment		15,616,186
Pharmacy Services segment		6,559,560
Intersegment elimination		(247,353)
Total revenue	$	21,928,393

Accounting Standards Update 2016-02

Schedule of impact of the Company's adoption of the ASU on the prior period consolidated balance sheet

	Impact of change in accounting policy
(in thousands)	As reported				As adjusted
	March 2, 2019		Adjustments		March 3, 2019
ASSETS
Current assets:
Cash and cash equivalents	$	144,353	$	—	$	144,353
Accounts receivable, net		1,788,712		—		1,788,712
Inventories, net		1,871,941		—		1,871,941
Prepaid expenses and other current assets		179,132		(51,448)		127,684
Current assets held for sale		117,581		43,697		161,278
Total current assets		4,101,719		(7,751)		4,093,968
Property, plant and equipment, net		1,308,514		—		1,308,514
Operating lease right-of-use asset		—		3,026,976		3,026,976
Goodwill		1,108,136		—		1,108,136
Other intangibles, net		448,706		(29,632)		419,074
Deferred tax assets		409,084		—		409,084
Other assets		215,208		(1,086)		214,122
Total assets	$	7,591,367	$	2,988,507	$	10,579,874
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations	$	16,111	$	—	$	16,111
Accounts payable		1,618,585		—		1,618,585
Accrued salaries, wages and other current liabilities		808,439		(56,553)		751,886
Current portion of operating lease liabilities		—		457,305		457,305
Current liabilities held for sale		—		45,167		45,167
Total current liabilities		2,443,135		445,919		2,889,054
Long-term debt, less current maturities		3,454,585		—		3,454,585
Long-term operating lease liabilities		—		2,838,022		2,838,022
Lease financing obligations, less current maturities		24,064		—		24,064
Other noncurrent liabilities		482,893		(238,658)		244,235
Total liabilities		6,404,677		3,045,283		9,449,960
Commitments and contingencies		—		—		—
Stockholders’ equity:
Common stock, par value $1 per share; 75,000 shares authorized; shares issued and outstanding 54,016		54,016		—		54,016
Additional paid-in capital		5,876,977		—		5,876,977
Accumulated deficit		(4,713,244)		(56,776)		(4,770,020)
Accumulated other comprehensive loss		(31,059)		—		(31,059)
Total stockholders’ equity		1,186,690		(56,776)		1,129,914
Total liabilities and stockholders’ equity	$	7,591,367	$	2,988,507	$	10,579,874

Accounting Standards Update 2014-09

Schedule of impact of the Company's adoption of the ASU on the prior period consolidated balance sheet

	Impact of Change in Accounting Policy
	As Reported				Adjusted
In thousands	March 3, 2018		Adjustments		March 4, 2018
Consolidated Balance Sheet:
Accounts receivable, net	$	1,869,100	$	(57,897)	$	1,811,203
Inventories, net		1,799,539		51,121		1,850,660
Deferred tax assets		594,019		(1,784)		592,235
Total assets		8,989,327		(8,560)		8,980,767
Accumulated deficit		(4,282,471)		(8,560)		(4,291,031)
Total shareholders’ equity		1,601,010		(8,560)		1,592,450